Ibrutinib plus CD19-specific CAR T-ce... - CLL Support Assoc...

CLL Support Association
13,263 members20,817 posts

Ibrutinib plus CD19-specific CAR T-cell therapy may benefit patients with relapsed or refractory CLL

Administration of ibrutinib beginning 2 weeks prior to leukapheresis and continuing until 3 months after CD19-specific chimeric antigen receptor T-cell therapy appeared well tolerated among patients with relapsed or refractory chronic lymphocytic leukemia, according to retrospective study results presented at ASH Annual Meeting and Exposition.


1 Reply

Interesting research. Hopefully this will make CAR-T more tolerable to patients, and with fewer side-effects.


You may also like...